Coming together in the global fight against cancer

Global Women's Cancer Summit

The Global Summit on Women’s Cancers took place this week

What do an astronaut, a former First Lady and a CSI: Miami actress have in common?

They were all speakers at Monday’s Global Summit on Women’s Cancers, held on the annual World Cancer Day (see our earlier blog post for our thoughts on this).

The event was hosted by Susan G. Komen For The Cure – a US-based breast cancer charity –and we were there to hear specifically about global efforts against breast and cervical cancers.

The agenda was packed, and while it might seem like a strange list of speakers, astronaut Ronald J Garan Jr, former First Lady Laura Bush and CSI: Miami actress Eva La Rue all had their own unique insights to offer on beating cancer worldwide.

But before the main talks, the conference opened with an inspiring video which really brought home the key message: that collaboration is essential if we are to beat cancer, and that every individual effort makes a difference.

Continue reading

Health Committee report: we need decisions on cancer drugs

Health Select Committee - screenshot

Professor Peter Johnson (far right) gives evidence to the Committee

Today, the Health Committee – a cross-party group of MPs appointed to scrutinise the Department of Health’s policies – published a report on its inquiry into NICE – the body that determines which treatments the NHS should pay for.

The Committee looked at how the drugs regulator works, ahead of the appointment of its new chair, Professor David Haslam.

Their final report makes a number of recommendations relevant to cancer patients, so here’s a detailed look at what it says, and what we think about it.

Continue reading

Abiraterone available across the UK… finally!

Man in hospital

Abiraterone can give valuable extra months of life

We’re delighted with today’s news that abiraterone will be available for men with advanced prostate cancer on the NHS in Scotland.

This is fantastic for Scottish men with the disease as it brings them in line with the rest of the UK, which has been able to access the drug since the NICE ruling back in May.

This is the second time the Scottish Medicines Consortium (SMC) – which assesses whether drugs offer good value for money – has looked at the drug, having turned it down in March. The pharmaceutical company, Janssen, offered a better deal this time around, which enabled the SMC to say yes.

This is a great decision that we’re really pleased to see. But it has been too long in coming and raised important questions about how drugs are made available across the UK. As we have said before, we need the processes by which medicines are assessed to be streamlined so that patients are not left in limbo. And we need the regulators and pharmaceutical companies to work together to get the best outcome for patients.

Abiraterone is not a cure for prostate cancer, but it can give men with the disease precious extra months of life to spend with friends and family. We’re really proud of our involvement in developing the drug, and in telling NICE, the SMC and Janssen why we think they should work together to get it approved. It is a real success story when years of hard work in the lab turn into effective treatments for patients.

And we couldn’t do any of this without the generous funds from you – our supporters. Thank you.

A look back on the Year of Radiotherapy

Handing in our petition to number 10 Downing Street

Our 'Voice for Radiotherapy' campaign petition garnered over 36,000 signatures

As 2011 drew to a close, so too did the Year of Radiotherapy.

The aim of the Year, which we’ve blogged about before, was to improve public understanding and raise awareness of this important form of treatment, which receives less attention than cancer drugs, yet cures more people.

We achieved a lot over the last 12 months, bringing the UK closer to having world class radiotherapy services. Here’s a quick run-down of what happened, and when.

Continue reading

The Government’s new Giving white paper – will it work?

David Cameron

David Cameron launched the government's Giving White Paper yesterday

Yesterday, David Cameron launched the Government’s greatly anticipated Giving White Paper as part of its Big Society agenda. This builds on their Green Paper published in December and a consultation exercise in which they asked people for their thoughts on giving.

The White Paper sets out measures to help create what the Government calls ‘social norms of giving and volunteering’ – initiatives that will help get people more involved with charities.

Cancer Research UK is the UK’s largest fundraising charity. We receive no Government funding for our research and rely on the generosity of the public to fund our work. We also have around 45,000 fantastic volunteers who give their time to help us, so we’ve been reading the proposals with great interest.

Continue reading

To ‘Commit to Beat Cancer’, the Government must tackle inequalities

We want the next government to tackle cancer inequalities

Cancer Research UK’s ‘Commit to Beat Cancer’ campaign calls on parliamentary candidates to pledge to keep cancer high on the political agenda. Over the last few weeks we’ve been exploring some of the issues behind these calls, looking at how Government could protect the UK’s research base and provide access to new treatments..

This week, Heather Walker, policy researcher at Cancer Research UK, explains why all parties should commit to tackle cancer inequalities.

“We need not accept the present size of the social gradient in health as fixed. If it can change, and we can understand why, action is possible to reduce it.”

- Professor Sir Michael Marmot

Early this year, the Marmot Report – a Government-sponsored review of how the health system treats different sectors of society – concluded that health inequalities are strongly linked to things like a person’s income and social background.  As the report found, a man living in the wealthiest part of London can expect to live to 88 years, while in one of the poorest parts of the capital, male life expectancy is just 71.

The issue is not a new one – the Black Report in 1980 said the same, and yet, thirty years on, inequalities persist. And tackling inequalities isn’t easy, as successive Governments have found. But that doesn’t mean we shouldn’t try.

There’s plenty of evidence that inequalities are a real problem throughout the cancer journey, from prevention right through to treatment, and ultimately, mortality and survival.

With regard to prevention, we know that smoking is more prevalent among more deprived groups and this means that these people are more likely to develop smoking-related diseases, such as cancer.

We know that there are inequalities in access to cancer treatments too. To take just one example, a 2007 study in the British Journal of Cancer found that older women are less likely to receive standard treatment for breast cancer than their younger counterparts.  Furthermore, this trend increased with age so that the oldest women fared least well.

And looking at survival, a 2004 review by the National Audit Office found that unskilled workers were twice as likely to die from cancer as professionals.

There are many other groups that experience a whole range of inequalities in cancer. And these can be complex. For example, you might be surprised to learn that people from the most affluent areas are more likely to develop skin cancer. Despite this, however, they have better survival rates than those from the more deprived areas.

Cancer Research UK believes that we should work together to end cancer inequalities. We want the next Government to ensure that everyone has the best chance to beat cancer, regardless of where they live, how well-off they are, their ethnicity, gender, language or indeed, any other factor.

Continue reading